Manual for EWOG MDS 2006, Initial Registration

	Variable	Definition
	Date of onset	Date of first sign/symptom/abnormal CBC associated with MDS/JMML.
		Date of first biopsy/BM aspirate
	Date of diagnosis	(retrospectively) indicating MDS/JMML
		JMML without Noonan Syndrome
		JMML-like disorder and Noonan Syndrome
		MDS
		Refractory cytopenia (RC)
		(PB blasts <2% and BM blasts <5%)
		Refractory anemia with excess blasts (RAEB)
		(PB blasts 2-19% or BM blasts 5-19%)
		RAEB in transformation (RAEB-T)
	Diagnosis	(PB or BM blasts 20-29%)
Clinical features and		
physical examination at		
diagnosis	Fatigue	yes = NCI grade \geq 1
	Fever (>38°C)	
	Active infection	infection requiring medical attention
	Respiratory tract symptoms	
	Bleeding	yes = NCI grade \geq 1
	Skin rash	any rash
	Spleen size	in cm below costal margin by palpation
	Liver size	in cm below costal margin by palpation
	Lymphadenopathy (>1,5cm)	any lymph node > 1,5cm
	Enlarged tonsils	Abnormally large for age
	Chloroma	Only recently developed as seene much as a f MDC/ IMM
	Diehetee in die in de	Only recently developed as consequence of MDS/JMML.
	Diabetes insipidus	Exclude long-standing diabetes insipidus
	Blasts in CSF	Any blast in cytocentrifuge preparation
Associated pathology/ medical history of the patient	Other signs or symptoms	
pation		café-au-lait macules over 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter
	Café au lait spots	in postpubertal individuals
	number	
	other symptoms of NF1	
	First degree relative with NF1	
	Previous congenital bone marrow	e.g. Fanconi anemia, severe congential neutropenia and
	failure disorder	others
	Previous acquired bone marrow	
	failure disorder	e.g. aplastic anemia, PNH
	Previous malignancy	
	Date of diagnosis	
		name of protocol, if not according protocol give
	Previous chemotherapy	chemotherapy
	Previous radiotherapy	includes radiotherapy administered according to protocol
	Mental retardation	
	Clinical evidence of PNH	yes = thrombosis or hemolysis
	Hepatitis	ALT,SGPT > 2.5 - 5.0 x ULN (WHO grade 2)
F	Other abnormalities	Exclude consequences of previous therapy
Family history in		
1° relatives	Parents are cousins	
	History of malignancies	
	Hemato-/Immunological diseases	
	Other possibly relevant diseases	

	LDH elevated for age and	
	laboratory	
Laboratory data	range of normal	
Laboratory data	Uric acid elevated for age and	
	laboratory range of normal	
	HbA ₂	prior to transfusion or ≥ 6 weeks after last transfusion
		•
	HbF	prior to transfusion or \geq 6 weeks after last transfusion
	Coombs test	positive or negative
	IgA	
	IgM	
	lgG	
	Ferritin	
	HLA type	
	stool elastasis	
	Trypsinogene in serum	
	Isoamylase in serum	
	EBV-VCA IgG/IgM	
	EBV-EA IgG/IgM	
	EBV-EBNA IgG/IgM	
	Herpes Simplex IgG/IgM	
	HBV IgG/IgM	
	HIV	
	CMV IgG/IgM	
	HHV6 IgG/IgM	
	Parvovirus B19 IgG/IgM	
	HCV IgG/IgM	
Cytogenetic and	Date of conventional cytogenetic	
Culture studies	examination	
	Fanconi	
	PTPN11/ RAS	
	In vitro studies performed	
Hematological data		
at diagnosis	Hb	Date of first BM smear suspicious for MDS/JMML
	MCV	pretransfusion levels
	Platelets	pretransfusion levels
	WBC	
	Ery	pretransfusion levels
	Reti	pretransfusion levels
		Should add to 100, but because of calculations may add up
	Differential count (%)	97-103.
	Cell content	
	Megakaryocytes	
	Auer rods	
		Should add to 100, but because of calculations may add up
	Differential count	97-103.
	Name of reviewing center	
Previous therapy	Therapy prior to diagnosis	